Cooperative Agreement U01FD007909
Award Date
9/5/24
Completion Date
8/31/27
Dollars Obligated
$1.5M
Funding Federal Agency
Office of the Commissioner
Awarding Federal Agency
FDA Office of Acquisition and Grant Services
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
93.103
Assistance Type
Cooperative Agreement
Place of Performance
Durham, NC 27710, USA
Similar Awards
This Cooperative Agreement award from the Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) provides $1,496,492.00 to the Sloan-Kettering Institute for Cancer Research to conduct research on elucidating tumor-specific cell surface proteomes in ultra-rare cancers like rhabdoid tumors and desmoplastic small round cell tumors. The goal is to gain a better understanding of these challenging, therapy-resistant cancers and identify potential new therapeutic targets. The...
This $4,653,104 Cooperative Agreement award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to discover and develop small molecule agents that can modulate the PAX3-FOXO1 fusion oncoprotein driving the highly fatal fusion-positive alveolar rhabdomyosarcoma (FP-RMS) cancer. The project involves a multi-institutional team with expertise in high-throughput screening, chemoproteomics, molecular biology, medicinal chemistry, and pharmacology. Key goals...
The National Cancer Institute (NCI) awarded a $581,381 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research. The 5-year grant, effective June 5, 2025, will fund research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance in cancer. The key products of this research will be a better understanding of DNA damage repair pathways and how they contribute...
The federal Project Grant award, issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), provides $1,944,610.00 in funding to the Sloan-Kettering Institute for Cancer Research to conduct research on understanding tumorigenesis and identifying therapeutic targets in CDK12-mutant prostate cancer. The research, which has a performance period from Apr 1, 2025 to Mar 31, 2028, involves a sub-award to the University of Texas MD Anderson Cancer...
This Project Grant award from the Food and Drug Administration (FDA) Research program (CFDA 93.103) provides $385,592 to the Sloan-Kettering Institute for Cancer Research to conduct a Phase II clinical trial of the drug combination of avutometinib plus defactinib for the treatment of rare, aggressive types of thyroid cancer. The trial will focus on radioiodine-refractory, recurrent and/or metastatic differentiated thyroid cancer (DTC) and anaplastic thyroid cancer (ATC), which currently have...
This federal Project Grant award of $2,808,108.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the Sloan-Kettering Institute for Cancer Research to investigate the role of clonal hematopoiesis in therapeutic resistance and metastatic relapse in breast cancer. The award period extends from March 1, 2024 to February 29, 2028. Through this funding, the Sloan-Kettering Institute will explore the...
This federal Cooperative Agreement award, funded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research to develop the first genetically engineered mouse model of desmoplastic small round cell tumor (DSRCT) and define its pathobiology. The $527,904 award, which runs from September 1, 2024 to August 31, 2029, aims to: 1) establish a DSRCT mouse model by inducing the EWSR1-WT1 gene fusion and studying the effects of...
This $627,833 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) aims to develop an informatics platform that integrates molecular and pathological data from various lung cancer preclinical models and patient tumors. The goal is to assess the fidelity of these preclinical models through comparative analyses. The University of Texas Southwestern Medical Center, the prime awardee, will work with Duke University as a sub-awardee to...
This $2,372,456 Project Grant awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support a collaborative research program led by Memorial Sloan Kettering Cancer Center focused on leveraging observational (real-world) data to advance precision oncology. The key products and services to be delivered include: Overcoming methodological barriers in the analysis of observational clinico-genomic data (Project 1) Addressing the role of genetic ancestry...
This federal Cooperative Agreement award in the amount of $485,790 was issued on May 1, 2025 by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The award is being provided to the University of Massachusetts Medical School (UMass Medical) in Worcester, MA to study the efficacy of tyrosine kinase inhibitors, such as imatinib, in restoring DNA damage response and preventing the onset of hematologic malignancies in patients with familial...